Tokai raises $35.5m to continue prostate cancer trials
This article was originally published in Scrip
Executive Summary
The day after Bayer Healthcare received FDA approval for its prostate cancer drug Xofigo, venture investors have once again backed Tokai's lead product galeterone (TOK-001), which is in development for the same indication. Tokai has raised $35.5 million in Series E financing for its ongoing Phase II trial for galeterone as a treatment for castration-resistant prostate cancer (CRPC).